Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

How Can We Destigmatize a Hepatitis B Diagnosis? Conversations Between Patient and Physician #2

Source: Addressing Key Challenges in Viral Hepatitis Management
In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B.
Jacki Chen, PhD
Robert G. Gish, MD
Released: February 24, 2022

In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B. The conversation focuses on the stigma many patients experience following diagnosis and how access to treatment may reduce this.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Robert G. Gish, MD

Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno School of Medicine
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director
Hepatitis B Foundation
Washington, DC

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimmune, Antios, Arrowhead, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Topography Health, Venatorx, and Viking; has served on advisory boards for Abbott, AbbVie, Altimunne, Antios, Arrowhead, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Venatorx, and Viking; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect.
Jacki Chen, PhD

Patient

Jacki Chen, PhD, has disclosed that he has received consulting fees from GlaxoSmithKline.

Program Medium

This program has been made available online.

Related Content

Clinical Care Options (CCO) expert audio: Dr Carla Coffin discusses investigational HBV cure strategies

person default Carla Coffin, MD Released: June 30, 2022

Drs. Kosh Agarwal and Graham R. Foster discuss linkage to care for patients with HDV, from Clinical Care Options (CCO)

Kosh Agarwal, MD Graham R. Foster, FRCP, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: June 30, 2022 Expired: June 29, 2023

Clinical Care Options (CCO) commentary from a patient who shares their experience of severe liver disease from HBV/HDV coinfection

person default Joaquín (Patient) Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 29, 2022 Expired: June 28, 2023

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings